Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 24, 2026, 11:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Anaemia, Sickle Cell Clear all
Recruiting Not applicable Interventional

Ultrasound Acute Chest Syndrome Sickle Cell Disease

NCT06880679
View directory record Official record
Conditions
Acute Chest Syndrome, Sickle Cell Disease
Interventions
Point of Care Ultrasound
Device
Lead sponsor
Indiana University
Other
Eligibility
Up to 25 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Jul 24, 2026, 11:13 PM EDT
Recruiting Not applicable Interventional

Predictors of Pain in Sickle Cell Disease

NCT06139510
View directory record Official record
Conditions
Sickle Cell Disease, Chronic Pain
Interventions
Quantitative sensory testing
Other
Lead sponsor
Duke University
Other
Eligibility
15 Years to 40 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Jul 24, 2026, 11:13 PM EDT
Completed Not applicable Interventional

Parent Educational Program for Children With Sickle Cell Disease

NCT00860782
View directory record Official record
Conditions
Hemoglobin SC Disease, Anemia, Sickle Cell
Interventions
Parent Educational Support
Behavioral
Lead sponsor
University of Miami
Other
Eligibility
6 Years to 12 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 1, 2021 · Synced Jul 24, 2026, 11:13 PM EDT
Withdrawn Phase 1 Interventional

US Phase I Study of ECT-001-CB in Patients With Sickle-Cell Disease

NCT04594031
View directory record Official record
Conditions
Sickle Cell Disease, Umbilical Cord Blood, Hematopoietic Cell Proliferation
Interventions
ECT-001-CB (UM171-Expanded Cord Blood Transplant)
Biological
Lead sponsor
ExCellThera inc.
Industry
Eligibility
5 Years to 30 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Palo Alto, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 4, 2022 · Synced Jul 24, 2026, 11:13 PM EDT
Completed Not applicable Interventional

Acupuncture for Pain in Sickle Cell Disease

NCT04122378
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
acupuncture
Other
Lead sponsor
Deepika Darbari
Other
Eligibility
8 Years to 22 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Dec 3, 2024 · Synced Jul 24, 2026, 11:13 PM EDT
Terminated Phase 3 Interventional Results available

Study to Assess the Effect of Long-term Treatment With Voxelotor in Participants Who Have Completed Treatment in Study GBT440-031

NCT03573882
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Voxelotor
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years to 65 Years
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
34
States / cities
Little Rock, Arkansas • Oakland, California • Miami, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2025 · Synced Jul 24, 2026, 11:13 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Study Evaluating the Safety and Efficacy of EDIT-301 in Participants With Severe Sickle Cell Disease (RUBY)

NCT04853576
View directory record Official record
Conditions
Sickle Cell Disease, Hemoglobinopathies
Interventions
EDIT-301
Genetic
Lead sponsor
Editas Medicine, Inc.
Industry
Eligibility
12 Years to 50 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
21
States / cities
Oakland, California • Aurora, Colorado • New Haven, Connecticut + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2025 · Synced Jul 24, 2026, 11:13 PM EDT
Withdrawn Early Phase 1 Interventional

Androgen Regulation of Priapism in Sickle Cell Disease

NCT01940718
View directory record Official record
Conditions
Priapism, Sickle Cell Disease, Hypogonadism
Interventions
Transdermal Androgel
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 50 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 18, 2017 · Synced Jul 24, 2026, 11:13 PM EDT
Completed Phase 2 Interventional Results available

Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 or 24 Weeks in Genotype 1 or 4 HCV Infected Adults With Sickle Cell Disease

NCT02301936
View directory record Official record
Conditions
Hepatitis C Virus Infection
Interventions
LDV/SOF
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Lutherville, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 18, 2018 · Synced Jul 24, 2026, 11:13 PM EDT
Completed Phase 1 Interventional

Pharmacokinetics (PK) of Liquid Hydroxyurea in Pediatric Patients With Sickle Cell Anemia

NCT01506544
View directory record Official record
Conditions
Sickle Cell Anemia
Interventions
Hydroxyurea
Drug
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
2 Years to 17 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
6
States / cities
Birmingham, Alabama • Chicago, Illinois • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2014 · Synced Jul 24, 2026, 11:13 PM EDT
Completed Phase 4 Interventional Results available

Rejuvesol® Washed RBC in Sickle Cell Patients Requiring Frequent Transfusions

NCT02731157
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Rejuvesol, Blood transfusion
Drug · Procedure
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 24, 2019 · Synced Jul 24, 2026, 11:13 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Phase I/II Pilot Study of Mixed Chimerism to Treat Hemoglobinopathies

NCT01419704
View directory record Official record
Conditions
Anemia, Sickle Cell, Complex and Transfusion-dependent Hemoglobinopathies, Thalassemia, Diamond-Blackfan Anemia, Bone Marrow Failure Syndromes, Alpha-Thalassemia, Beta-Thalassemia
Interventions
Enriched Hematopoetic Stem Cell Infusion
Biological
Lead sponsor
Talaris Therapeutics Inc.
Industry
Eligibility
Up to 45 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
3
States / cities
Chicago, Illinois • Louisville, Kentucky • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 2, 2023 · Synced Jul 24, 2026, 11:13 PM EDT
Recruiting Phase 3 Interventional

A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia

NCT06609226
View directory record Official record
Conditions
Sickle Cell Disease, Thalassemia
Interventions
Etavopivat A, Etavopivat B, Etavopivat C
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
2 Years and older
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
36
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Jul 24, 2026, 11:13 PM EDT
Terminated Phase 2 Interventional Results available

Efficacy of Vorinostat to Induce Fetal Hemoglobin in Sickle Cell Disease

NCT01000155
View directory record Official record
Conditions
Sickle Cell Disease, Sickle Cell Anemia
Interventions
vorinostat
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 20, 2017 · Synced Jul 24, 2026, 11:13 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

Haploidentical PBMC Transplant for Severe Congenital Anemias

NCT00977691
View directory record Official record
Conditions
Sickle Cell Anemia
Interventions
PBSC Transplant, Alemtuzumab, Sirolimus, Cyclophosphamide, Low Dose Irradiation
Procedure · Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
2 Years to 80 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Jul 24, 2026, 11:13 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Macrolide Therapy to Improve Forced Expiratory Volume in 1 Second in Adults With Sickle Cell Disease

NCT02960503
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Azithromycin, Placebo
Drug · Other
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 50 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 1, 2018 · Synced Jul 24, 2026, 11:13 PM EDT
Terminated No phase listed Observational

Pharmacokinetic (PK) and Pharmacodynamics (PD) Study of Ilera Specific Products

NCT03886753
View directory record Official record
Conditions
ALS, Autism Spectrum Disorder, Cancer, Spasticity, Muscle, Dyskinetic Syndrome, Epilepsy, Glaucoma, Huntington Disease, Inflammatory Bowel Disease (IBD), Multiple Sclerosis, Neuropathy, Opioid Use, Parkinson Disease, HIV/AIDS, Ptsd, Intractable Pain, Sickle Cell Disease, Terminal Illness
Interventions
Registry, PK microsampling of blood
Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
2 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 29, 2020 · Synced Jul 24, 2026, 11:13 PM EDT
Terminated Phase 3 Interventional

THE IMPROVE TRIAL: Improving Pain Management and Outcomes With Various Strategies of Patient-Controlled Analgesia (PCA)

NCT00999245
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
High Demand / Low Infusion, PCA Dosing Plan
Other
Lead sponsor
Carelon Research
Other
Eligibility
10 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
28
States / cities
Oakland, California • New Haven, Connecticut • Wilmington, Delaware + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2013 · Synced Jul 24, 2026, 11:13 PM EDT
Recruiting Phase 1 Interventional

PET Imaging of Vaso-Occlusive Crisis (VOC) in SCD

NCT04925492
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Positron Emission Tomography, Cu-64]-LLP2A
Radiation · Drug
Lead sponsor
Enrico Novelli
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 6, 2025 · Synced Jul 24, 2026, 11:13 PM EDT
Terminated Phase 1 Interventional

Study of Safety and Efficacy of Genome-edited Hematopoietic Stem and Progenitor Cells in Sickle Cell Disease (SCD)

NCT04443907
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
OTQ923
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years to 40 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
3
States / cities
Chicago, Illinois • New York, New York • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Jul 24, 2026, 11:13 PM EDT
Completed Not applicable Interventional

BEATS 2: Music Therapy in Sickle Cell

NCT03233269
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Music Therapy
Behavioral
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years to 35 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 21, 2018 · Synced Jul 24, 2026, 11:13 PM EDT
Active, not recruiting Phase 2 Interventional

Acute GVHD Suppression Using Costimulation Blockade to Expand Non-malignant Transplant

NCT03924401
View directory record Official record
Conditions
Graft Versus Host Disease
Interventions
Abatacept
Drug
Lead sponsor
Emory University
Other
Eligibility
Up to 20 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
9
States / cities
Birmingham, Alabama • Wilmington, Delaware • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Jul 24, 2026, 11:13 PM EDT
Completed Not applicable Interventional

Hyperbaric Oxygen Therapy in Sickle Cell Pain

NCT03412045
View directory record Official record
Conditions
Vaso-occlusive Crisis, Sickle Cell Anemia Crisis
Interventions
hyperbaric oxygen therapy
Device
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Jan 1, 2026 · Synced Jul 24, 2026, 11:13 PM EDT
Completed Phase 2 Interventional Results available

Nitrous Oxide Analgesia Vaso-occlusive Crisis

NCT01891812
View directory record Official record
Conditions
Sickle Cell Disease, Vaso-occlusive Crisis
Interventions
Nitrous oxide 50%
Drug
Lead sponsor
Columbia University
Other
Eligibility
8 Years to 18 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Jul 24, 2026, 11:13 PM EDT